Jim Cramer advises caution on Mobileye Global and favors Eli Lilly over Cassava Sciences in Alzheimer's trials. Jim Cramer aconseja precaución en Mobileye Global y favorece a Eli Lilly sobre Cassava Sciences en los ensayos de Alzheimer.

On "Mad Money," host Jim Cramer addressed stock inquiries during a lightning round. En "Mad Money", el presentador Jim Cramer abordó las consultas sobre acciones durante una ronda relámpago. He noted that while Cassava Sciences is engaged in an Alzheimer's trial, Eli Lilly's formulation is viewed as superior. Anotó que aunque Cassava Sciences participa en un ensayo sobre el Alzheimer, la formulación de Eli Lilly se considera superior. Cramer advised caution regarding Mobileye Global, stating he would avoid investing due to uncertainty. Cramer aconsejó cautela con respecto a Mobileye Global, afirmando que evitaría invertir debido a la incertidumbre.